Advocacy Group Urges FDA to Sift Through Avastin Glioblastoma Data—Agency Accepts
Guest Editorial: Myriad Ruling Becomes a Textbook Case Of How Not To Manage a Patent Portfolio, by Robert Cook-Deegan
Patenting the Gene: Cancer Advocates and Industry Diverge on Myriad Ruling
FASEB: Focus on Research Funding, Not PR
MD Anderson Researcher Charged With Placing Ethylene Glycol In Colleague’s Coffee
Trending Stories
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.” - At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival









